# PURE Bioscience, Inc. (PURE) · Edgar & Edgarette company card

> PURE Bioscience (PURE) grew revenue 5.3% in FY2026 to $2 million, operating margin -89.9% against a -0.2% median for miscellaneous chemical products, equity -536% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1006028 · fiscal year ended 2026-07-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/PURE) · [JSON](https://www.pops4.com/boards/company/PURE.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $2M |
| Revenue growth, 1 year | 5.3% |
| Revenue growth per year | 5.8% |
| Operating margin | -89.9% (prior year -103.2%) |
| Net margin | -107.1% |
| Operating cash flow | −$2M |
| Capital spending | — |
| Free cash flow | — |
| Cash | $569,000 |
| Long-term debt | $7M |
| Total assets | $1M |
| Total equity | −$6M |
| Equity ÷ assets | -536.4% |
| Return on equity | — |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -416.74 (distress zone)
- Piotroski F: 2 of 9 (weak)
- Beneish M: null (below the −1.78 line)
- Health Harbor boat: Rotting at the dock · four or more warning signs · liabilities exceed assets (often from years of share buybacks, not always distress); operating cash flow was negative; operating loss: a margin of -89.9% in FY2026; revenue is hard to predict: its 80% range is ±59%
- Cash Compass: In between · no clear cash pattern yet

## Edgarette's reading

Exposure: revenue $2.3M (FY2026), total debt $6.6M. Experience: revenue up 5.3% on the year, up 5.8% a year over 4 years; operating margin -89.9%, up from -103.2%. Soundness: equity -536.4% of assets (liabilities exceed assets). Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $1.2M and $4.8M next year (method v4.1: its own 6-year record of growth weighed at 63% against under $50M filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $1.1M to $5.3M. A statistical range, not company guidance. Against peers (224 filers, $50M+ revenue, its industry group): operating margin -89.9% against a -0.2% median; growth 5.3% against 6.7%.

Range logged 2026-10-30, receipt b8d9be3d0c9f85ee, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 5.02 Director or officer change: 1, latest 2025-11-19 ([filing](https://www.sec.gov/Archives/edgar/data/1006028/000149315225024276/0001493152-25-024276-index.htm))

## Recent filings

- 10-K · filed 2026-10-29 · [filing](https://www.sec.gov/Archives/edgar/data/1006028/000149315226049272/0001493152-26-049272-index.htm)
- 8-K · filed 2026-10-29 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1006028/000149315226049265/0001493152-26-049265-index.htm)
- 8-K · filed 2026-10-20 · 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1006028/000149315226047762/0001493152-26-047762-index.htm)
- 10-Q · filed 2026-06-15 · [filing](https://www.sec.gov/Archives/edgar/data/1006028/000149315226028691/0001493152-26-028691-index.htm)
- 8-K · filed 2026-06-15 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1006028/000149315226028686/0001493152-26-028686-index.htm)
- 8-K · filed 2026-05-05 · 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1006028/000149315226021329/0001493152-26-021329-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001006028.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1006028

## Cite

POPS4, Edgar & Edgarette: PURE Bioscience, Inc. (PURE) company card, from the company's own SEC filings, accessed 2026-11-18, https://www.pops4.com/boards/company/PURE. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.

